ME01106B - Derivati karboksamida kao antagonisti muskarinskih receptora - Google Patents

Derivati karboksamida kao antagonisti muskarinskih receptora

Info

Publication number
ME01106B
ME01106B MEP-2009-96A MEP9609A ME01106B ME 01106 B ME01106 B ME 01106B ME P9609 A MEP9609 A ME P9609A ME 01106 B ME01106 B ME 01106B
Authority
ME
Montenegro
Prior art keywords
alkyl
optionally substituted
halo
independently selected
receptor antagonists
Prior art date
Application number
MEP-2009-96A
Other languages
English (en)
Inventor
Paul Alan Glossop
Simon John Mantell
Ross Sinclair Strang
Christine Anne Louise Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ME01106B publication Critical patent/ME01106B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

GDJE R1 je CN ili CONH2;A je odabrano odPri čemu * i ** predstavljaju mjesta vezivanja. ** je vezan za kiseonik. - R2 i R3 su metil ilikada je A, grupa formule R2 i R3 mogu takode sa atomom ugljenika za koji su vezani formiraju ciklopentanski prsten;p je 0 ili 1; A1 je odabran oda) fenila po izboru supstituisanog sa 1, 2 ili 3 grupe nezavisno odabrane od halo, CN, CF3,OR4, SR4, OCF3, (C|-C4)alkil i fenil po izboru supstituisan sa OH; 4 4b) naftila po izboru supstituisanog sa 1 ili 2 grupe odabrane od halo, CN, CF3, OR, SR, OCF3 i (Ci-C4)alkil;c) 9 ili 10-člane biciklične aromatične heterociklične grupe, koja sadrži od 1, 2 ili 3 heteroatomanezavisno odabrana od O, S ili N, podaci heterociklična grupa je po izboru supstituisanasa 1 ili 2 supstituenta nezavisno odabrana od OR4, (Ci-COalkil i halo; - R4 je H ili (C,-C4)alkil; ili, ukoliko je to pogodno, njihove farmaceutski prihvatljive soli ili solvati.Patent sadrži još 24 patentnih zahtjeva.
MEP-2009-96A 2005-09-21 2006-09-01 Derivati karboksamida kao antagonisti muskarinskih receptora ME01106B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71946805P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21
PCT/IB2006/002727 WO2007034325A1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
ME01106B true ME01106B (me) 2013-03-20

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-96A ME01106B (me) 2005-09-21 2006-09-01 Derivati karboksamida kao antagonisti muskarinskih receptora

Country Status (43)

Country Link
US (3) US7772223B2 (me)
EP (1) EP1928821B1 (me)
JP (1) JP4221447B1 (me)
KR (1) KR100976909B1 (me)
CN (1) CN101268046B (me)
AP (1) AP1983A (me)
AR (1) AR055171A1 (me)
AT (1) ATE420069T1 (me)
AU (1) AU2006293618B9 (me)
BR (1) BRPI0616111B8 (me)
CA (1) CA2623332C (me)
CR (2) CR9814A (me)
CU (1) CU20100115A7 (me)
CY (1) CY1108880T1 (me)
DE (1) DE602006004768D1 (me)
DK (1) DK1928821T3 (me)
DO (1) DOP2006000202A (me)
EA (1) EA013083B1 (me)
EC (1) ECSP088265A (me)
ES (1) ES2318794T3 (me)
GE (1) GEP20104880B (me)
GT (1) GT200600422A (me)
HK (1) HK1117163A1 (me)
HN (1) HN2006032615A (me)
HR (1) HRP20090127T3 (me)
IL (1) IL189453A (me)
MA (1) MA29839B1 (me)
ME (1) ME01106B (me)
MX (1) MX2008002805A (me)
MY (1) MY143581A (me)
NL (1) NL2000241C2 (me)
NO (1) NO340975B1 (me)
NZ (1) NZ566023A (me)
PE (1) PE20070460A1 (me)
PL (1) PL1928821T3 (me)
PT (1) PT1928821E (me)
RS (2) RS51680B (me)
SI (1) SI1928821T1 (me)
TN (1) TNSN08137A1 (me)
TW (1) TWI322143B (me)
UY (1) UY29798A1 (me)
WO (1) WO2007034325A1 (me)
ZA (1) ZA200801432B (me)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
DE602007005387D1 (de) * 2006-09-22 2010-04-29 Pfizer Ltd Ptors
SI2125714T1 (sl) * 2007-03-16 2011-10-28 Pfizer Ltd Hidrokloridna sol 5-(3-(3-hidroksifenoksi)azetidin-1-il)-5-metil-2,2-difenilheksanamida
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
WO2018167804A1 (en) 2017-03-15 2018-09-20 Mylan Laboratories Limited Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112021005140A8 (pt) 2018-09-19 2021-06-29 Corteva Agriscience Llc preparação de análogos de halogênio de picloram
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
US20220380307A1 (en) * 2019-06-25 2022-12-01 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ATE235903T1 (de) * 1996-12-02 2003-04-15 Kyorin Seiyaku Kk Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
DE59611439D1 (de) * 1996-12-17 2007-09-06 Filtertek Bv Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規n−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
MXPA04006206A (es) 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
CN1681789A (zh) 2002-09-17 2005-10-12 埃科特莱茵药品有限公司 1-吡啶-4-基-脲衍生物

Also Published As

Publication number Publication date
PL1928821T3 (pl) 2009-06-30
CA2623332A1 (en) 2007-03-29
AR055171A1 (es) 2007-08-08
KR20080037103A (ko) 2008-04-29
US20100029720A1 (en) 2010-02-04
AU2006293618B2 (en) 2009-10-08
EA013083B1 (ru) 2010-02-26
PT1928821E (pt) 2009-03-10
NO340975B1 (no) 2017-07-31
HN2006032615A (es) 2010-10-04
CN101268046A (zh) 2008-09-17
US20070105831A1 (en) 2007-05-10
EP1928821A1 (en) 2008-06-11
EP1928821B1 (en) 2009-01-07
PE20070460A1 (es) 2007-05-14
MY143581A (en) 2011-05-31
RS50855B (sr) 2010-08-31
BRPI0616111B1 (pt) 2019-10-08
US8486992B2 (en) 2013-07-16
EA200800540A1 (ru) 2008-08-29
US7772223B2 (en) 2010-08-10
HK1117163A1 (en) 2009-01-09
AP1983A (en) 2009-03-24
AU2006293618A1 (en) 2007-03-29
HRP20090127T3 (en) 2009-06-30
US20110251164A1 (en) 2011-10-13
NL2000241A1 (nl) 2007-03-22
UY29798A1 (es) 2007-04-30
DOP2006000202A (es) 2007-04-15
RS20080119A (en) 2009-05-06
TNSN08137A1 (fr) 2009-07-14
ECSP088265A (es) 2008-04-28
AU2006293618B9 (en) 2009-10-29
CU20100115A7 (es) 2011-10-14
GT200600422A (es) 2007-05-28
JP4221447B1 (ja) 2009-02-12
MX2008002805A (es) 2008-04-07
NO20081001L (no) 2008-03-25
DK1928821T3 (da) 2009-03-16
RS51680B (en) 2011-10-31
CY1108880T1 (el) 2014-07-02
WO2007034325A1 (en) 2007-03-29
CR20130209A (es) 2013-09-19
JP2009508933A (ja) 2009-03-05
TWI322143B (en) 2010-03-21
ATE420069T1 (de) 2009-01-15
IL189453A (en) 2014-06-30
CR9814A (es) 2008-04-16
MA29839B1 (fr) 2008-10-03
DE602006004768D1 (de) 2009-02-26
CU23910B1 (me) 2013-06-29
NL2000241C2 (nl) 2009-01-05
ZA200801432B (en) 2009-07-29
SI1928821T1 (sl) 2009-04-30
TW200745024A (en) 2007-12-16
GEP20104880B (en) 2010-01-11
NZ566023A (en) 2010-02-26
KR100976909B1 (ko) 2010-08-18
IL189453A0 (en) 2008-08-07
ES2318794T3 (es) 2009-05-01
BRPI0616111B8 (pt) 2021-05-25
US8268881B2 (en) 2012-09-18
CN101268046B (zh) 2012-07-25
BRPI0616111A2 (pt) 2011-06-07
CA2623332C (en) 2012-05-01

Similar Documents

Publication Publication Date Title
ME01106B (me) Derivati karboksamida kao antagonisti muskarinskih receptora
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
EA200870362A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
ATE556058T1 (de) 1-(2h)-isochinolonderivat
RS52999B (en) BIS (AMIDIDA TIO-HYDRAZIDE) Salts for Cancer Treatment
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
RS52520B (en) ACT AND P70 S6 KINASE INHIBITORS
NO20060206L (no) Nye azetidinforbindelser
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
CY1112449T1 (el) Υποκατεστημενα ν-βενζο [d] ισοξαζολ-3-υλ-αμινο παραγωγα ως αναστολεις υποδοχεων mglur5, σεροτονινης-(5-ητ) και νοραδρεναλινης και η χρηση αυτων για την παραγωγη φαρμακων
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
PE20080254A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
BRPI0516381A (pt) derivados de cromano e seu uso como ligandos de receptor de 5-ht
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
ATE540675T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
FR2894578B1 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
NO20081220L (no) Nytt cercosporamidderivat
TNSN08161A1 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
NO20080458L (no) Derivater av 4,5-diarylpyrrol, fremstilling derav og anvendelsen derav i terapi
NO20072454L (no) Pyridinderivater, fremstillingen og den terapeutiske anvendelse derav
ATE248147T1 (de) Piperidine derivate als inhibitoren der neurotransmitter-wiederaufbaunahme